News
The FDA has postponed its decision date for Regenxbio’s Hunter syndrome gene therapy to review additional longer-term ...
Adaptive Biotechnologies lost a powerhouse partner after Roche subsidiary Genentech walked away from a potentially $2 billion ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results